Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD

Nucleic acid vaccines have been proven to be a revolutionary technology to induce an efficient, safe and rapid response against pandemics, like the coronavirus disease (COVID-19). Minicircle DNA (mcDNA) is an innovative vector more stable than messenger RNA and more efficient in cell transfection an...

Full description

Bibliographic Details
Main Authors: Cathy Ventura, Dalinda Eusébio, Ana M. Gonçalves, Jorge Barroca-Ferreira, Diana Costa, Zhengrong Cui, Luís A. Passarinha, Ângela Sousa
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/10/5/990
_version_ 1797501380181622784
author Cathy Ventura
Dalinda Eusébio
Ana M. Gonçalves
Jorge Barroca-Ferreira
Diana Costa
Zhengrong Cui
Luís A. Passarinha
Ângela Sousa
author_facet Cathy Ventura
Dalinda Eusébio
Ana M. Gonçalves
Jorge Barroca-Ferreira
Diana Costa
Zhengrong Cui
Luís A. Passarinha
Ângela Sousa
author_sort Cathy Ventura
collection DOAJ
description Nucleic acid vaccines have been proven to be a revolutionary technology to induce an efficient, safe and rapid response against pandemics, like the coronavirus disease (COVID-19). Minicircle DNA (mcDNA) is an innovative vector more stable than messenger RNA and more efficient in cell transfection and transgene expression than conventional plasmid DNA. This work describes the construction of a parental plasmid (PP) vector encoding the receptor-binding domain (RBD) of the S protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the use of the Design of Experiments (DoE) to optimize PP recombination into mcDNA vector in an orbital shaker. First, the results revealed that host cells should be grown at 42 °C and the Terrific Broth (TB) medium should be replaced by Luria Broth (LB) medium containing 0.01% L-arabinose for the induction step. The antibiotic concentration, the induction time, and the induction temperature were used as DoE inputs to maximize the % of recombined mcDNA. The quadratic model was statistically significant (<i>p</i>-value < 0.05) and presented a non-significant lack of fit (<i>p</i>-value > 0.05) with a suitable coefficient of determination. The optimal point was validated using 1 h of induction, at 30 °C, without the presence of antibiotics, obtaining 93.87% of recombined mcDNA. Based on these conditions, the production of mcDNA was then maximized in a mini-bioreactor platform. The most favorable condition obtained in the bioreactor was obtained by applying 60% pO<sub>2</sub> in the fermentation step during 5 h and 30% pO<sub>2</sub> in the induction step, with 0.01% L-arabinose throughout 5 h. The yield of mcDNA-RBD was increased to a concentration of 1.15 g/L, when compared to the orbital shaker studies (16.48 mg/L). These data revealed that the bioreactor application strongly incremented the host biomass yield and simultaneously improved the recombination levels of PP into mcDNA. Altogether, these results contributed to improving mcDNA-RBD biosynthesis to make the scale-up of mcDNA manufacture simpler, cost-effective, and attractive for the biotechnology industry.
first_indexed 2024-03-10T03:17:34Z
format Article
id doaj.art-83e76953dab24fe580126a64b805b387
institution Directory Open Access Journal
issn 2227-9059
language English
last_indexed 2024-03-10T03:17:34Z
publishDate 2022-04-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj.art-83e76953dab24fe580126a64b805b3872023-11-23T10:09:28ZengMDPI AGBiomedicines2227-90592022-04-0110599010.3390/biomedicines10050990Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBDCathy Ventura0Dalinda Eusébio1Ana M. Gonçalves2Jorge Barroca-Ferreira3Diana Costa4Zhengrong Cui5Luís A. Passarinha6Ângela Sousa7CICS-UBI-Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, PortugalCICS-UBI-Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, PortugalCICS-UBI-Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, PortugalCICS-UBI-Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, PortugalCICS-UBI-Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, PortugalDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USACICS-UBI-Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, PortugalCICS-UBI-Health Science Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha, PortugalNucleic acid vaccines have been proven to be a revolutionary technology to induce an efficient, safe and rapid response against pandemics, like the coronavirus disease (COVID-19). Minicircle DNA (mcDNA) is an innovative vector more stable than messenger RNA and more efficient in cell transfection and transgene expression than conventional plasmid DNA. This work describes the construction of a parental plasmid (PP) vector encoding the receptor-binding domain (RBD) of the S protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the use of the Design of Experiments (DoE) to optimize PP recombination into mcDNA vector in an orbital shaker. First, the results revealed that host cells should be grown at 42 °C and the Terrific Broth (TB) medium should be replaced by Luria Broth (LB) medium containing 0.01% L-arabinose for the induction step. The antibiotic concentration, the induction time, and the induction temperature were used as DoE inputs to maximize the % of recombined mcDNA. The quadratic model was statistically significant (<i>p</i>-value < 0.05) and presented a non-significant lack of fit (<i>p</i>-value > 0.05) with a suitable coefficient of determination. The optimal point was validated using 1 h of induction, at 30 °C, without the presence of antibiotics, obtaining 93.87% of recombined mcDNA. Based on these conditions, the production of mcDNA was then maximized in a mini-bioreactor platform. The most favorable condition obtained in the bioreactor was obtained by applying 60% pO<sub>2</sub> in the fermentation step during 5 h and 30% pO<sub>2</sub> in the induction step, with 0.01% L-arabinose throughout 5 h. The yield of mcDNA-RBD was increased to a concentration of 1.15 g/L, when compared to the orbital shaker studies (16.48 mg/L). These data revealed that the bioreactor application strongly incremented the host biomass yield and simultaneously improved the recombination levels of PP into mcDNA. Altogether, these results contributed to improving mcDNA-RBD biosynthesis to make the scale-up of mcDNA manufacture simpler, cost-effective, and attractive for the biotechnology industry.https://www.mdpi.com/2227-9059/10/5/990bioreactorCOVID-19design of experimentsminicircle DNA vaccine
spellingShingle Cathy Ventura
Dalinda Eusébio
Ana M. Gonçalves
Jorge Barroca-Ferreira
Diana Costa
Zhengrong Cui
Luís A. Passarinha
Ângela Sousa
Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD
Biomedicines
bioreactor
COVID-19
design of experiments
minicircle DNA vaccine
title Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD
title_full Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD
title_fullStr Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD
title_full_unstemmed Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD
title_short Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD
title_sort maximization of the minicircle dna vaccine production expressing sars cov 2 rbd
topic bioreactor
COVID-19
design of experiments
minicircle DNA vaccine
url https://www.mdpi.com/2227-9059/10/5/990
work_keys_str_mv AT cathyventura maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd
AT dalindaeusebio maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd
AT anamgoncalves maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd
AT jorgebarrocaferreira maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd
AT dianacosta maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd
AT zhengrongcui maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd
AT luisapassarinha maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd
AT angelasousa maximizationoftheminicirclednavaccineproductionexpressingsarscov2rbd